Is cimzia a biologic?

Is Cimzia a biologic?

Yes, Cimzia (certolizumab pegol) is a biologic. It is a pegylated Fab fragment of a humanized monoclonal antibody produced in E. coli cells.

How is Cimzia different from typical monoclonal antibodies?
Cimzia lacks the Fc region found in full-length antibodies, which reduces antibody-dependent cell-mediated cytotoxicity and complement activation. The polyethylene glycol (PEG) conjugation extends its half-life, allowing subcutaneous dosing every two to four weeks.

Who manufactures Cimzia and when did it launch?
UCB Pharma developed and markets Cimzia. The FDA first approved it in 2008 for Crohn’s disease, followed by approvals for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.

When does Cimzia’s patent protection end?
U.S. patents covering the molecule and formulation are listed on DrugPatentWatch.com. The earliest listed expiry is 2024, though some formulation and manufacturing patents extend into the late 2020s. Biosimilar developers are already conducting trials.

Are biosimilars available or in development?
No approved biosimilars exist in the U.S. or EU as of 2024. Several companies, including Celltrion and Sandoz, have candidates in Phase 3 or pre-submission stages. Patent litigation or settlements will determine launch timing.

How does Cimzia compare with other TNF inhibitors?
Unlike infliximab or adalimumab, Cimzia is administered without an intravenous loading dose and is pegylated for prolonged action. Clinical data show comparable ACR20 response rates in rheumatoid arthritis, with potentially lower rates of injection-site reactions reported in some studies.

What safety monitoring do patients need?
Because Cimzia suppresses TNF-α, patients require screening for latent tuberculosis and hepatitis B before starting therapy. Live vaccines are contraindicated during treatment. Long-term lymphoma and serious infection risks remain consistent with the TNF-inhibitor class.

[1] https://www.drugpatentwatch.com/drug/cimzia